Responses
Other responses
Jump to comment:
- Published on: 20 April 2012
- Published on: 16 April 2012
- Published on: 20 April 2012Industry-sponsored cost-effectiveness study of TAVIShow More
The potential cost-effectiveness (CE) of adopting innovative procedures within a publically funded healthcare system is a recurring issue.[1] Trans-catheter aortic valve insertion (TAVI) is not currently provided by the devolved National Health Service (NHS) in Scotland, although a single high quality randomised controlled clinical trial (RCT) has demonstrated that TAVI is a clinically effective intervention for reducin...
Conflict of Interest:
None declared. - Published on: 16 April 2012Important cost categories not included: TAVI probably less cost-effectiveShow More
Patients eligible for the TAVI intervention are old (>75), face a high mortality risk and generally have multiple comorbidities [1]. Health care consumption of this group of patients can therefore expected to be high [2,3]. As a consequence, life extension in this group would probably result in additional health care consumption in so-called life years gained. Health care consumption in life years gained could be due...
Conflict of Interest:
None declared.